Phaseline

Targets › TYMS

TYMS (Thymidylate synthase): drug programs, companies and trials

74 programs from 59 companies in 88 trials: 56 Phase 2, 20 Phase 3, 11 Phase 1, 1 Phase 4; Oncology, Other; next expected readout Nov 2026.

Catalyzes the reductive methylation of 2'-deoxyuridine 5'-monophosphate (dUMP) to thymidine 5'-monophosphate (dTMP), using the cosubstrate, 5,10- methylenetetrahydrofolate (CH2H4folate) as a 1-carbon donor and reductant and contributes to the mitochondrial and nuclear de novo thymidylate biosynthesis pathway. (UniProt, P04818)

Open in Phaseline: the race on TYMS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Duke UniversityFloxuridine
Thymidylate synthase inhibitor
TYMSPhase 4Pancreatic Ductal AdenocarcinomaDec 2028
Assistance Publique - Hôpitaux de ParisModified FOLFIRINOX
Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit
TOPO1, TOPO2A, MTHFR, TYMSPhase 3Rectal CancerDec 2026
Kyungpook National University HospitalFOLFOX-6
Combination chemotherapy: oxaliplatin (platinum agent), leucovorin (reduced folate), and 5
DPYD, TYMS, DHFRPhase 3Colon CancerDec 2026
Institut de Recherches Internationales ServierTrifluridine/tipiracil hydrochloride (S95005)
Thymidylate synthase inhibitor; trifluridine is an antimetabolite that inhibits thymidylat
TYMSPhase 3Metastatic Colorectal CancerDec 2026
Centre Hospitalier Universitaire Dijonmodified FOLFOX
Multi-drug chemotherapy: folate antagonist (folinic acid), thymidylate synthase inhibitor
TOPO2, TYMS, DHFR, SLC22A16Phase 3Colon Cancer; Locally Advanced or Metastatic Small Bowel AdenocarcinomaFeb 2027
Shandong Cancer Hospital and InstituteTAS-102
Trifluridine/tipiracil - nucleoside analogue with thymidine phosphorylase inhibitor
TYMSPhase 3Rectal CancerJun 2027
First Affiliated Hospital, Sun Yat-Sen UniversityInduction Chemotherapy (TPF regimen)
Docetaxel, cisplatin, and 5-fluorouracil combination
Tubulin, TP53, TYMS, RRM1Phase 3Locally Advanced Nasopharyngeal CarcinomaAug 2027
Seoul National University HospitalmFOLFIRINOX (preoperative)
Multi-agent chemotherapy combining irinotecan (topoisomerase I inhibitor), fluorouracil (t
TOPO1, DHFR, TYMSPhase 3Resectable Pancreatic CancerDec 2027
Chinese University of Hong KongFLOT
Combination chemotherapy: 5-fluorouracil (5-FU) inhibits thymidylate synthase; Leucovorin
TYMSPhase 3Cancer of Stomach, AdenocarcinomaDec 2027
Chinese University of Hong KongXELOX
Combination chemotherapy: Capecitabine (oral 5-FU prodrug) inhibits thymidylate synthase;
TYMSPhase 3Cancer of Stomach, AdenocarcinomaDec 2027
Fudan UniversityXELOX adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent) and capecitabine (5-fluorouracil pr
DHFR, TYMS, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
Fudan UniversitymFOLFIRINOX adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent), irinotecan (topoisomerase I inhibi
DHFR, TYMS, TOPO1, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
Fudan UniversitymFOLFOX6 adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent), leucovorin (folinic acid), and 5-f
DHFR, TYMS, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
Sun Yat-sen UniversityXELOX
Oxaliplatin (platinum agent) combined with capecitabine (prodrug of 5-fluorouracil/TYMS in
TYMSPhase 3Rectal CancerSep 2028
Kyungpook National University HospitalFOLFOX
Combination chemotherapy: 5-fluorouracil + leucovorin + oxaliplatin
DHFR, TYMSPhase 3Colon CancerDec 2028
ECOG-ACRIN Cancer Research GroupFloxuridine
Thymidylate synthase inhibitor
TYMSPhase 3Metastatic Colorectal CarcinomaJun 2029
Zhejiang Cancer Hospital5-FU monotherapy
DNA-damaging chemotherapy; inhibits thymidylate synthase
TYMSPhase 3Colon CancerDec 2029
The Netherlands Cancer InstituteFloxuridine
Thymidylate synthase inhibitor
TYMSPhase 3Colorectal NeoplasmsJan 2030
Sixth Affiliated Hospital, Sun Yat-sen UniversityCapeOx chemotherapy regimen
Capecitabine/oxaliplatin combination chemotherapy
TYMS, DHFRPhase 3Colorectal CancerFeb 2031
Sixth Affiliated Hospital, Sun Yat-sen UniversityFOLFOX chemotherapy regimen
5-FU/leucovorin/oxaliplatin combination chemotherapy
TYMS, DHFRPhase 3Colorectal CancerFeb 2031
Centre Hospitalier Universitaire DijonTrifluridine tipiracil
Thymidylate synthase inhibitor (trifluridine) with thymidine phosphorylase inhibitor (tipi
TYMSPhase 3Colon or Upper Rectum AdenocarcinomaMay 2032
LIN YANGtrifluridine/tipiracil (TAS-102)
Thymidylate synthase inhibitor; prodrug converted to active metabolite
TYMSPhase 2Gastric Cancer Adenocarcinoma MetastaticNov 2026
Henan Cancer HospitalTAS-102
Thymidylate synthase inhibitor (prodrug: trifluridine and tipiracil combination)
TYMSPhase 2Colorectal CancerNov 2026
Peking Union Medical College HospitalXELOX regimen
Capecitabine + oxaliplatin combination chemotherapy
TYMSPhase 2Locally Advanced Rectal AdenocarcinomaDec 2026
Cancer Institute and Hospital, Chinese Academy of Medical SciencesS-1
Fluorouracil prodrug; inhibits thymidylate synthase and orotate phosphoribosyltransferase
TYMS, OPRTPhase 2Biliary Tract Cancer; Pancreatic Adenocarcinoma; Intrahepatic Cholangiocarcinoma (Icc); Neuroendocrine TumorsDec 2026
Qilu Hospital of Shandong UniversityS-1
Fluoropyrimidine antimetabolite (tegafur, gimeracil, oteracil potassium)
TYMSPhase 2HER2-positive Gastric CancerDec 2026
Ruijin HospitalS-1
Oral fluoropyrimidine (tegafur/5-FU/gimeracil/oteracil combination)
TYMS, DHFRPhase 2Pancreatic Neoplasms; Gastric or Esophagogastric Junction AdenocarcinomaDec 2026
Rutgers, The State University of New JerseysFOLFOXIRI (alternating FOLFOX and FOLFIRI)
Fluorouracil-based chemotherapy combining FOLFOX (5-fluorouracil, leucovorin, oxaliplatin)
DHFR, TYMS, TOPO1Phase 2Gastro-Intestinal CancerFeb 2027
Taichung Veterans General HospitalNALIRIFOX
Liposomal irinotecan (topoisomerase I inhibitor) in combination with fluorouracil (thymidy
TOP1, TYMSPhase 2Resectable Pancreatic AdenocarcinomaFeb 2027
Centre Hospitalier Universitaire DijonFOLFOXIRI Protocol (modified FOLFIRINOX)
Combination chemotherapy: irinotecan (TOPO1 inhibitor) + oxaliplatin (TOPO2 inhibitor) + f
TOPO1, TOPO2, TYMSPhase 2Locally Advanced or Metastatic Small Bowel Adenocarcinoma; Neuroendocrine CarcinomaFeb 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesSOX
S-1 and oxaliplatin combination chemotherapy
TYMSPhase 2Gastric CancerMar 2027
Fudan UniversityTAS-102
Thymidylate synthase inhibitor; prodrug metabolized to FdUMP and FUTP
TYMSPhase 2Metastatic Colorectal Cancer (CRC)Apr 2027
Zhen-Hai LuXELOX
Oxaliplatin + capecitabine; platinum-based chemotherapy combined with fluoropyrimidine
TYMSPhase 2Advanced Rectal CancerMay 2027
Memorial Sloan Kettering Cancer Centerfloxuridine
Thymidylate synthase inhibitor
TYMSPhase 2Colorectal Cancer; Intrahepatic CholangiocarcinomaMay 2027
Lithuanian University of Health SciencesFOLFOX4
Combination chemotherapy with oxaliplatin (platinum agent), 5-fluorouracil (thymidylate sy
DHFR, TYMSPhase 2Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOXJun 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyS-1
Fluoropyrimidine combination (5-FU prodrug with CDHP and OXO)
TYMS, DHFRPhase 2Gastric CancerJul 2027
Peking University Cancer Hospital & Institutetegafur, gimeracil and oteracil potassium (SOX)
fluoropyrimidine-based regimen; thymidylate synthase inhibitor
TYMSPhase 2Hepatoid Adenocarcinoma of StomachSep 2027
The First Affiliated Hospital with Nanjing Medical University5-FU/LV
5-fluorouracil with leucovorin potentiation (thymidylate synthase inhibitor)
TYMSPhase 2Pancreatic CancerSep 2027
Qingdao Central HospitalTAS-102
5-FU prodrug with thymidylate synthase and dihydrofolate reductase inhibition
TYMS, DHFRPhase 2EFSDec 2027
St. Olavs HospitalFOLFOX
Combination chemotherapy with oxaliplatin (platinum-based DNA alkylating agent), 5-fluorou
TYMSPhase 2Tumor, ColorectalDec 2027
Tianjin Medical University Cancer Institute and Hospital5-FU/LV
Fluoropyrimidine antimetabolite with leucovorin potentiation
TYMSPhase 2Intrahepatic Cholangiocarcinoma (Icc)Dec 2027
Fudan UniversityFOLFOX
Combination of 5-fluorouracil (thymidylate synthase inhibitor), leucovorin (folate cofacto
TYMSPhase 2ctDNADec 2027
UMC UtrechtFTD-TPI
Thymidylate synthase inhibitor
TYMSPhase 2Metastatic Colorectal CancerJan 2028
Michael J Cavnar, MDFloxuridine
Thymidylate synthase inhibitor
TYMSPhase 2Colorectal Cancer MetastaticFeb 2028
Mayo ClinicPemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 2Metastatic Salivary Gland CarcinomaFeb 2028
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTegafur
Thymidylate synthase inhibitor (prodrug of 5-FU)
TYMSPhase 2Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaMar 2028
Fudan UniversitymFOLFIRINOX plus IMRT
Multi-drug chemotherapy regimen (5-fluorouracil, folinic acid, irinotecan, oxaliplatin) co
TOPO1, DPYD, TYMS, DHFRPhase 2Pancreatic Adenocarcinoma; Pancreatic CancerMar 2028
Ciusss de L'Est de l'Île de MontréalModified early post-operative intraperitoneal chemotherapy (mEPIC)
Intraperitoneal fluorouracil chemotherapy
TYMSPhase 2Peritoneal CarcinomatosisMay 2028
Dartmouth-Hitchcock Medical Centermodified FOLFIRINOX (mFOLFIRINOX)
Combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin; multi-targeted che
TYMS, DHFRPhase 2Pancreas AdenocarcinomaJul 2028
M.D. Anderson Cancer CenterTrifluridine and Tipiracil Hydrochloride
Thymidylate synthase inhibitor with bioavailability enhancer
TYMSPhase 2Refractory Colorectal CarcinomaAug 2028
Erasmus Medical CenterFloxuridin
Thymidylate synthase inhibitor (via fluorouracil metabolite)
TYMSPhase 2Intrahepatic Bile Duct CancerSep 2028
University of Wisconsin, MadisonTAS102
Thymidylate synthase inhibitor and nucleoside analog
TYMSPhase 2Metastatic Colorectal CancerSep 2028
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityTegafur
Antimetabolite (prodrug of fluorouracil)
TYMS, DHFRPhase 2ImmunotherapySep 2028
UNICANCERLonsurf (Trifluridine/tipiracil)
Thymidylate synthase inhibitor and DHFR inhibitor combination; trifluridine is a nucleosid
TYMS, DHFRPhase 2Metastatic Colorectal CancerOct 2028
The Methodist Hospital Research Institute5FU/LV
5-Fluorouracil (5FU) is a thymidylate synthase inhibitor; leucovorin (LV) enhances 5FU eff
TYMSPhase 2Metastatic Colorectal Cancer (CRC)Dec 2028
Corewell Health WestFloxuridine
Thymidylate synthase inhibitor
TYMSPhase 2Pancreatic AdenocarcinomaDec 2028
NRG OncologyPemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 2Recurrent Non-Small Cell Lung CarcinomaDec 2028
Centre Georges Francois LeclercFOLFIRINOX3
Combination chemotherapy: 5-FU (thymidylate synthase inhibitor), irinotecan (topoisomerase
TYMS, DHFRPhase 2Metastatic Pancreatic CancerJul 2029
Duke UniversityFLOT
5-FU + Leucovorin + Oxaliplatin + Docetaxel (antimetabolite + folinic acid + platinum alky
TYMS, DHFRPhase 2Esophageal AdenocarcinomaSep 2029
Duke UniversityModified-FOLFOX-6
5-FU + Leucovorin + Oxaliplatin (5-FU thymidylate synthase inhibitor + folinic acid + plat
TYMS, DHFRPhase 2Esophageal AdenocarcinomaSep 2029
Dominik Paul ModestTrifluridine/Tipiracil Hydrochloride
Thymidylate synthase inhibitor and thymidine phosphorylase inhibitor
TYMSPhase 2Metastatic Colorectal CancerDec 2029
Ruijin HospitalSOX
S-1 (tegafur/gimeracil/oteracil) + oxaliplatin chemotherapy regimen
TYMSPhase 2Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaMay 2030
Oslo University HospitalFloxuridine
Thymidylate synthase inhibitor
TYMSPhase 2Intrahepatic CholangiocarcinomaJan 2031
Ashish ShahDB107-FC
Flucytosine; prodrug converted by cytosine deaminase to fluorouracil
TYMS, DHFRPhase 2High Grade GliomaMay 2034
Sunnybrook Health Sciences CentreFloxuridine
Thymidylate synthase inhibitor
TYMSPhase 2Colorectal Adenocarcinoma Metastatic in the LiverDec 2036
Qilu Hospital of Shandong UniversityRaltitrexed
Thymidylate synthase inhibitor
TYMSPhase 2Intrahepatic Cholangiocarcinoma–
University of California, IrvineTAS-102
Thymidylate synthase inhibitor (trifluoridine); irinotecan topoisomerase I inhibitor combi
TYMSPhase 1Colon AdenocarcinomaJan 2027
Clinica Universidad de Navarra, Universidad de NavarraTTFields
Combination chemotherapy: folate antagonist (5-FU/leucovorin), topoisomerase I inhibitor (
TYMS, DHFRPhase 1Pancreatic Adenocarcinoma MetastaticMar 2027
National Cancer Institute (NCI)Pemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 1Epithelioid Mesothelioma; Biphasic MesotheliomaMar 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineRaltitrexed-PIPAC
Raltitrexed (thymidylate synthase inhibitor) delivered via pressurized intraperitoneal aer
TYMSPhase 1Peritoneal MetastasisOct 2027
National Health Research Institutes, TaiwanTrifluridine/Tipiracil (LONSURF)
Combination of nucleoside analog and thymidine phosphorylase inhibitor; inhibits thymidyla
TYMSPhase 1Metastatic Gastric AdenocarcinomaDec 2027
University of Colorado, DenverNALIRIFOX
Combination of liposomal irinotecan (topoisomerase I inhibitor), 5-fluorouracil (thymidyla
TOPO1, TOPO2A, TYMSPhase 1Pancreatic Ductal Adenocarcinoma (PDAC)Jul 2028
Roswell Park Cancer InstituteTrifluridine and Tipiracil Hydrochloride
Nucleoside analog (thymidine derivative) and thymidine phosphorylase inhibitor; inhibits D
TYMS, PNPPhase 1Advanced Malignant Solid NeoplasmSep 2028
Institute of Cancer Research, United KingdomIdetrexed
Folate receptor-targeted thymidylate synthase inhibitor
TYMS, FOLR1Phase 1High Grade Serous Ovarian CancerDec 2029

Conditions

Metastatic Colorectal Cancer (5) Colorectal Cancer (4) Colon Cancer (4) Gastric Cancer (3) Rectal Cancer (3) Pancreatic Adenocarcinoma (3) Intrahepatic Cholangiocarcinoma (3) High-risk Stage II Colorectal Cancer (3) Locally Advanced or Metastatic Small Bowel Adenocarcinoma (2) Metastatic Colorectal Cancer (CRC) (2) Esophageal Adenocarcinoma (2) Intrahepatic Cholangiocarcinoma (Icc) (2)

Modalities

small molecule (38), mixed (14), antibody (8), other (2)

Companies

Fudan University (6) Centre Hospitalier Universitaire Dijon (3) Duke University (3) Sixth Affiliated Hospital, Sun Yat-sen University (2) Ruijin Hospital (2) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) Qilu Hospital of Shandong University (2) Kyungpook National University Hospital (2) Chinese University of Hong Kong (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Lithuanian University of Health Sciences (1) The Methodist Hospital Research Institute (1) Michael J Cavnar, MD (1) The Netherlands Cancer Institute (1) Dartmouth-Hitchcock Medical Center (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) National Health Research Institutes, Taiwan (1) Shandong Cancer Hospital and Institute (1) Zhen-Hai Lu (1) Assistance Publique - Hôpitaux de Paris (1)

Related targets

DHFR (26) TOPO1 (7) SLC22A16 (4) GART (3) TOPO2 (2) TOPO2A (2) DPYD (2) MTHFR (1) Tubulin (1) TP53 (1) RRM1 (1) OPRT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.